European pharma group wants to create PRV-like system to spur antibiotics R&D
New research funded by a European pharma industry group is looking to reinvigorate antimicrobial R&D with a system that’s similar to the priority review voucher systems in the US, which spurs new research in rare pediatric diseases, rare tropical diseases and medical countermeasures.
As the need for novel antibiotics is urgent, EFPIA is calling for a Transferable Exclusivity Extension (TEE) voucher system where developers of novel antibiotics can win a voucher that can then be used to extend the exclusivity of another drug for a period of time, or sold to another company, thereby paying for the antibiotic research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.